62 research outputs found
Colorectal Cancer in People with Intellectual Disabilities
People with intellectual disabilities (PWIDs) are now living longer; thus, the incidence of cancer within this population is increasing. Available data indicate an excess of digestive tract cancers in PWIDs, but colorectal cancer has rarely been specifically studied and has not been extensively reviewed. This is despite risk factors such as being overweight, obesity, and lack of exercise being more frequent in PWIDs. In this article, we examine the literature on the frequency, screening, and treatment of colorectal cancer in PWIDs by as sessing 4 databases, Medline, EBSCO-CINHL, ASSIA, and PsychLIT, from 1970 to February 2017. Findings indicate that the frequency trends slightly higher than that found in the general population. Screening presents a unique opportunity to discover early colorectal cancer, but is underused in PWIDs compared to the general population. Furthermore, the clinical presentation is frequently masked, particularly by challenging behaviours, and colorectal cancer is therefore often diagnosed late, making treatment difficult due to the advanced stage of these tumours. To improve the care of PWIDs, we need more resources to support them and their caregivers, and to increase awareness of the risk factors and signs and symptoms of colorectal cancer
Gastroesophageal adenocarcinomas – Neoadjuvant and adjuvant treatments in 2011: A review
Les adénocarcinomes oesogastriques (AOG) représentent une des
premières causes de décès par cancer dans le monde. Alors que
l’incidence de l’adénocarcinome (ADK) gastrique diminue, celle de
l’ADK de la jonction oesogastrique augmente dans les pays occidentaux.
Le traitement chirurgical Ă©tant le seul traitement curatif et le taux
de survie à 5 ans dépendant du stade pTNM, la prise en charge
thérapeutique est un véritable challenge pour les oncologues.
Plusieurs modalités de traitement dont la chimiothérapie systémique
ont été évaluées afin de diminuer les récidives et d’augmenter la
survie globale. Cet article fait la mise au point en 2011 des traitements
adjuvants et néoadjuvants des AOG. Aux États-Unis, la radiochimiothérapie
postopératoire est préférée chez les patients en bon état
général ayant un AOG réséqué (> stade Ia) mais n’est applicable que
chez moins de la moitié des patients. Plus récemment, les FNCLCCFFCD
et la UK MAGIC ont clairement démontré que la chimiothérapie
périopératoire avait un bénéfice sur la survie globale des patients
opérables pour leur AOG ; ce traitement est un standard et il est
couramment réalisé en Europe. De nouvelles stratégies comme la
chimiothérapie d’induction suivie d’une radiochimiothérapie, l’addition
de thérapies ciblées à la chimiothérapie périopératoire ou l’utilisation
de nouveaux schémas de chimiothérapie sont en cours d’évaluation
afin d’augmenter le bénéfice des traitements standard actuels
Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
<p>Abstract</p> <p>Background</p> <p>The anti-VEGF antibody bevacizumab associated with an irinotecan or oxaliplatin-based chemotherapy was proved to be superior to the chemotherapy alone in first or second line treatment of metastatic colorectal cancer (mCRC). However, it was reported to have no efficacy in 3<sup>rd </sup>or later-line, alone or with 5FU. The aim of this study was to evaluate the activity of bevacizumab combined with FOLFIRI or FOLFOX in mCRC who have failed prior chemotherapy with fluoropyrimidine plus irinotecan and/or oxaliplatin.</p> <p>Methods</p> <p>Thirty one consecutive patients treated between May 2005 and October 2006 were included in this retrospective study. All of them have progressed under a chemotherapy with fluoropyrimidine plus irinotecan and/or oxaliplatin and received bevacizumab (5 mg/kg) in combination with FOLFIRI or simplified FOLFOX4 every 14 days.</p> <p>Results</p> <p>Ten patients (32.2%) had an objective response (1 CR, 9 PR) and 12 (38.8%) were stabilized. The response and disease control rates were 45.4% and 100% when bevacizumab was administered in 2<sup>nd </sup>or 3<sup>rd </sup>line and 25% and 55% in 4<sup>th </sup>or later line respectively (p = 0.024 and p = 0.008). Among the patients who had previously received the same chemotherapy than that associated with bevacizumab (n = 28) the overall response rate was 35.7% and 39.3% were stabilized. Median progression free survival (PFS) and overall survival (OS) were of 9.7 and 18.4 months respectively. Except a patient who presented a hypertension associated reversible posterior leukoencephalopathy syndrome, tolerance of bevacizumab was acceptable. A rectal bleeding occurred in one patient, an epistaxis in five. Grade 1/2 hypertension occurred in five patients.</p> <p>Conclusion</p> <p>This study suggests that bevacizumab combined with FOLFOX or FOLFIRI may have the possibility to be active in chemorefractory and selected mCRC patients who did not receive it previously.</p
Fréquence des néoplasies planes colorectales et concordances histo-endoscopique dans une série consécutive de polype
REIMS-BU Santé (514542104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
TAS-118 plus oxaliplatin in advanced gastric cancer: is it worth it?
International audienc
Neoadjuvant therapy for gastroesophageal adenocarcinoma
International audienceGastric and esophageal adenocarcinomas are one of the main causes of cancer-related death worldwide. While the incidence of gastric adenocarcinoma is decreasing, the incidence of gastroesophageal junction adenocarcinoma is rising rapidly in Western countries. Considering that surgical resection is currently the major curative treatment, and that the 5-year survival rate highly depends on the pTNM stage at diagnosis, gastroesophageal adenocarcinoma management is very challenging for oncologists. Several treatment strategies are being evaluated, and among them systemic chemotherapy, to decrease recurrences and improve overall survival. The MAGIC and FNCLCC-FFCD trials showed a survival benefit of perioperative chemotherapy in patients with operable gastric and lower esophageal cancer, and these results had an impact on the European clinical practice. New strategies, including induction chemotherapy followed by preoperative chemoradiotherapy, targeted therapies in combination with perioperative chemotherapy and the new cytotoxic regimens, are currently assessed to improve current standards and help developing patient-tailored therapeutic interventions
Colonic flat neoplasia: frequency and concordance between endoscopic appearance and histological diagnosis in a French prospective series.
The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer
International audienceIn 2010, the FOLFIRINOX regimen (bolus and infusional 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) emerged as a new option in patients with metastatic pancreatic cancer and a good performance status. However, at that time, some doubts were raised regarding safety issues. Similarly, no data on FOLFIRINOX were published in patients with unresectable/locally advanced or borderline resectable pancreatic cancer. This article presents the available experience with FOLFIRINOX outside clinical trials in metastatic and locally advanced pancreatic cancer patients. The safety of the regimen in patients with biliary stents and in previously treated patients is also described. FOLFIRINOX usage in clinical practice, including modification of the regimen (omission of bolus 5-fluorouracil; FOLFOXIRI regimen), is also presented. These data suggest that a phase III randomized study is warranted to further explore the role of FOLFIRINOX in locally advanced pancreatic cancer
Traitement des fistules œsophagiennes par l’injection de colle chimique (cyanoacrylate, Histoacryl®)
Le protocole FLOT est-il le nouveau standard de chimiothérapie péri-opératoire des cancers de l’estomac ?
- …